1.Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention.
Firas ABDOLLAH ; Alberto BRIGANTI ; Nazareno SUARDI ; Fabio CASTIGLIONE ; Andrea GALLINA ; Umberto CAPITANIO ; Francesco MONTORSI
Korean Journal of Urology 2011;52(8):507-516
Benign prostatic hyperplasia (BPH) is highly prevalent in older men and causes substantial adverse effects on health. The pathogenesis of this disease is not totally clear. Recent reports have suggested a possible relationship between metabolic syndrome (MetS) and BPH. Single components of MetS (obesity, dyslipidemia, hypertension, and insulin resistance) as well as the syndrome itself may predispose patients to a higher risk of BPH and lower urinary tract symptoms (LUTS). This may stem from changes in insulin resistance, increased autonomic activity, impaired nitrergic innervation, increased Rho kinase activity, pro-inflammatory status, and changes in sex hormones that occur in association with MetS. However, the exact underlying mechanisms that regulate the potential relationship between MetS and BPH/LUTS still need to be clarified. Increased physical activity and dietary strategies may help in decreasing the incidence of MetS and its impact on BPH/LUTS. However, differences in the definitions used to address the examined predictors and endpoints preclude the possibility of arriving at definitive conclusions.
Dyslipidemias
;
Gonadal Steroid Hormones
;
Humans
;
Hypertension
;
Incidence
;
Insulin
;
Insulin Resistance
;
Lower Urinary Tract Symptoms
;
Male
;
Motor Activity
;
Prostatic Hyperplasia
;
rho-Associated Kinases
2.Assessment of the gender gap in urology industry payments: An Open Payments Program data analysis
Yuzhi WANG ; Matthew James DAVIS ; Alexandra ROGERS ; Jonathan REXROTH ; Taylor Jane MALCHOW ; Alex STEPHENS ; Mohit BUTANEY ; Samantha WILDER ; Samantha RAFFEE ; Firas ABDOLLAH
Investigative and Clinical Urology 2024;65(4):411-419
Purpose:
The Open Payments Program (OPP), established in 2013 under the Sunshine Act, mandated medical device and pharmaceutical manufacturers to submit records of financial incentives given to physicians for public availability. The study aims to characterize the gap in real general and real research payments between man and woman urologists.
Materials and Methods:
The study sample included all urologists in the United States who received at least one general or research payment in the OPP database from 2015 to 2021. Recipients were identified using the National Provider Identifier and National Downloadable File datasets. Payments were analyzed by geography, year, payment type, and years since graduation.Multivariable analysis on odds of being in above the median in terms of money received was done with gender as a covariate. This analysis was also completed for all academic urologists.
Results:
There was a total of 15,980 urologists; 13.6% were woman, and 86.4% were man. Compared to man urologists, woman urologists were less likely to be in the top half of total payments received (odds ratio [OR] 0.62) when adjusted for other variables.When looking at academic urologists, 18.1% were woman and 81.9% were man. However, woman academic urologists were even less likely to be in the top 50% of payments received (OR 0.55).
Conclusions
This study is the first to characterize the difference in industry payments between man and woman urologists. The results should be utilized to educate physicians and industry, in order to achieve equitable engagement and funding for woman urologists.